Health Care M&A Deals, August 14, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is Bayer AG’s $425 million acquisition of KaNDy Therapeutics Ltd., which will give Bayer KaNDy’s NT-814, a potentially first in class receptor antagonist which showed positive findings for the treatment of moderate to severe vasomotor symptoms due to menopause. To subscribe to our Health Care M&A deals chart and more,... Read More »
Health Care M&A Deals, August 7, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was Teladoc Health, Inc.’s (NYSE: TDOC) acquisition of Livongo Health, Inc. (NASDAQ: LVGO) for $18.5 billion. The combination creates a global leader in consumer-centered virtual care. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for... Read More »
Health Care M&A Deals, July 31, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is a global development and commercialization agreement for DS-1062 between AstraZeneca plc and Daiichi Sankyo Company valued at $1 billion. DS-1062 is Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC), and potential new medicine for the treatment of multiple tumor types. The companies will... Read More »
Health Care M&A Deals, July 24, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was Dedalus Group’s acquisition of DXC’s healthcare software provider business for $525 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious analyst and investor. Every day, this service alerts you to... Read More »
Health Care M&A Deals, July 17, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was Genentech, Inc.’s collaboration on pralsetinib with Blueprint Medicines Corporation valued at $775 million. Blueprint Medicines and Genentech will co-commercialize pralsetinib and equally share profits in the U.S. Roche will obtain an exclusive license to commercialize pralsetinib outside the U.S., excluding Greater China. To subscribe to our... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
